Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Harmony Biosciences Holdings, Inc.

Get SEC filing alerts via email and in your feed for Harmony Biosciences Holdings, Inc.

HRMY

Harmony Biosciences Holdings, Inc.

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences is a neuroscience company focused on developing and commercializing treatments for rare neurological disorders. Its core product, WAKIX (pitolisant), addresses narcolepsy and related sleep disorders, offering a non-scheduled, first-in-class therapy with a novel mechanism. The company also advances pipeline candidates for hypersomnia, epilepsy, and neurobehavioral conditions, leveraging scientific innovation and strategic licensing to serve patients with limited treatment options.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Harmony Biosciences Holdings, Inc.

1
1
Harmony Biosciences Holdings, Inc. Harmony Biosciences Reports $215.4M Revenue and $32.5M Net Income in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Harmony Biosciences Holdings, Inc. Harmony Biosciences Reports 21.5% Revenue Growth to $868.5 Million in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Harmony Biosciences Holdings, Inc. Harmony Biosciences Reports 28.7% Revenue Growth to $239.5 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Harmony Biosciences Holdings, Inc. Harmony Biosciences Reports 16% Revenue Growth to $200.5 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Harmony Biosciences Holdings, Inc. Harmony Biosciences Reports 19.5% Revenue Growth to $184.7 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Harmony Biosciences Holdings, Inc. Harmony Biosciences Reports 16.1% Revenue Growth, Net Income Increase in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments